Nanocube Health Ltd. is developing accessible, low-cost nanorobots that could revolutionize diagnosis and treatment of hard-to-diagnose cancers, with pancreatic cancer being the initial focus.
In what represents the first patenting from Cerathrive Ltd., its co-founder and CEO, Sarah Turner, describes their development of the Cera system, which they claim to be the first and only U.S. FDA-cleared red-light device that targets the gut-brain axis to improve focus and energy levels.
In what represents its first patenting, Roseville, Minn.-based Iveacare Inc. provides insights as to what its first therapeutic target will likely be since the developer of neuromodulation therapy devices emerged from stealth mode in April 2024 with the closing of $27.5 million series A financing.
Australia is the skin cancer capital of the world, but with a shortage of dermatologists, patients often wait too long to get skin checks that could end up costing them their lives.
The first patenting from Encephalogix Inc. details its development of platform that uses machine learning and AI to analyze EEG data that is typically ignored.
In what represents Vienna, Austria-based Valeriot GmbH’s first patenting, its founder and CEO, Michael Flatscher, describes their invention of a device, Autovein, for use in no-touch vein harvesting which overcomes the issues faced with traditional vein harvesting techniques which are laborious, prone to complications and challenging to master.
In what represents the first patenting from Munich, Germany-based Meliodys Medical UG, its co-founder and chief executive officer Simone Sabbione describes their development of a hormone-free, local pain management approach for treating dysmenorrhea, which aims to address the condition while minimizing the occurrence of side effects.
Skin biopsies could be a thing of the past thanks to the development of a new non-invasive microneedle patch to pre-screen for skin cancer. Dermr Health Solutions Pty Ltd. founder and CEO Stefan Mazy told BioWorld that the fledgling genomics startup company is pushing the boundaries of science with its Dermr patch that quickly and painlessly extracts live skin cells in 15 seconds, drastically cutting the time and discomfort associated with traditional biopsy procedures.
The first patenting from Hemeo BV describes its development of Vantage, an artificial intelligence powered clinical decision support software for coagulation management.
In Ciconia Medical Inc.’s first patenting, the company’s founder and CEO, Roni Cantor-Balan, describes the development of a cervical measurement device for childbirth progress monitoring that replaces the manual vaginal examinations undertaken during labor.